 |
Previous Article | Next Article 
The Journal of Neuroscience, July 15, 1998, 18(14):5264-5274
The Activity of a Highly Promiscuous AP-1 Element Can Be Confined
to Neurons by a Tissue-Selective Repressive Element
Joseph R. M.
Weber and
J. H. Pate
Skene
Department of Neurobiology, Duke University Medical Center, Durham,
North Carolina 27710
 |
ABSTRACT |
Tissue-specific gene transcription can be determined by the use of
either positive-acting or negative-acting DNA regulatory elements. We
have analyzed a promoter from the growth-associated protein 43 (GAP-43)
gene and found that it uses both of these mechanisms to achieve its
high degree of neuron-specific activity. Two novel transcription factor
binding sites, designated Cx1 and Cx2, drive promoter activity in
neurons from developing cerebral cortex but not in several other cell
types. The promoter also contains an activator protein 1 (AP-1) site
that contributes to activity in neurons. The AP-1 site can drive
promoter activity in a wide range of non-neuronal cells that express
little or no endogenous GAP-43, but only in the absence of a
tissue-specific repressive element located downstream of the GAP-43
TATA box. These findings suggest that the GAP-43 repressive element
plays an important role in allowing AP-1 signaling pathways to modulate activity of the GAP-43 gene in neurons, without also causing
inappropriate activation by AP-1 transcription factors in other cell
types.
Key words:
AP-1; Cx1; Cx2; GAP-43; gene; transcription; neuron; repressive element; NGFI-A; SNOG element; BIPPUR element; TATA box
 |
INTRODUCTION |
The activation or repression of
specific genes during the course of neuronal differentiation, and
throughout adult life, often relies on signal-transducing pathways
common to many neuronal and non-neuronal cell types. Yet activation of
a particular signaling cascade can evoke a very different response in
neurons than in non-neuronal cells. For example, a number of
extracellular signaling events can activate AP-1 transcription factors
(Sheng and Greenberg, 1990 ; Herschman, 1991 ), but the set of genes that
are activated or repressed varies greatly depending on cell type and
history. What mechanisms allow a specific gene to respond to a
particular signaling pathway in one cell type, but not to the same
signaling pathway in a different cellular context?
We have examined this issue using a neuron-specific promoter from the
growth-associated protein 43 (GAP-43) gene. The GAP-43 gene, which
codes for an axonal growth cone protein, is widely expressed in
developing neurons during periods of axon elongation (Jacobson et al.,
1986 ; Skene, 1989 ) and is also expressed in glial cells under some
circumstances (Deloulme et al., 1993 ; Plantinga et al., 1993 ). Within
neurons, GAP-43 expression declines as synaptic contacts are
established but may be reactivated in response to axonal injury (Skene,
1992 ). Induction of GAP-43 after axotomy is correlated with activation
of c-Jun, a common component of AP-1 transcription factors
(Herdegen and Zimmermann, 1994 ; Schaden et al., 1994 ; Herdegen et al.,
1997 ), and the GAP-43 gene contains a phylogenetically conserved AP-1
consensus sequence (Groen et al., 1995 ). Despite widespread expression
of c-Jun and activation of AP-1-dependent pathways in many
cell types, however, the GAP-43 gene is expressed only in the nervous
system, and perhaps transiently in a few other cell types (Stocker et
al., 1992 ; Heuss et al., 1995 ; Anchan et al., 1997 ).
Several potential mechanisms could contribute to cell type-specific
activation of a commonly used response element such as an AP-1 site.
First, the sequence of the response element itself might be recognized
preferentially by some versions of the heterodimeric AP-1 transcription
factor (Hai and Curran, 1991 ; Karin et al., 1997 ). Second, the
effectiveness of AP-1 could be enhanced by cooperative binding with a
second factor that is more restricted in its tissue distribution
(Bassuk and Leiden, 1995 ). Thirdly, negative-acting and positive-acting
transcription factors could compete for the same binding site (Igarashi
et al., 1994 ). A fourth, more indirect mechanism is to use a
tissue-selective repressive element to counter activity that would
otherwise be driven by positive-acting elements recognized in many cell
types (Chong et al., 1995 ; Schoenherr and Anderson, 1995a ,b ).
We show here that the GAP-43 promoter uses this fourth mechanism to
produce neuron-specific activation through its AP-1 site. The conserved
AP-1 element in the GAP-43 gene can serve as an effective target for
activation in many different cell types, but the effect of this AP-1
mediated activation is counteracted in most cells by a separate
repressive element that restricts promoter activity to neurons. The
repressive element does not, however, account for all of the tissue
specificity of the small GAP-43 promoter we have focused on. We also
find that two novel protein binding sites located close to the AP-1
consensus element further contribute to neuron-specific gene expression
by boosting promoter activity in some populations of neurons.
 |
MATERIALS AND METHODS |
DNA constructs. The wild-type 386 bp GAP-43
promoter/luciferase reporter gene construct pGL3A-386 has been
described previously (Weber and Skene, 1997 ). The modified versions of
the 386 bp promoter shown in Figure 1 were produced by PCR in which
HindIII restriction sites were added to the ends of the PCR
primers. The E1b TATA box and transcription start site shown in Figure
2, which includes bases 34 to +11 of the sequence published by Wu and
coworkers (1987) , was made by annealing complementary oligonucleotides
and then cloning this fragment into the BglII and
HindIII sites of the plasmid pGL3A-Basic (Weber and Skene,
1997 ) to obtain pGL3A-Viral TATA. For the additional constructs in
Figure 2, BglII and BamHI sites were added to the
ends of the AP-1/Cx region (the 90 bp sequence beginning 59 bp
downstream of the GAP-43 TATA box) by PCR, and one or two copies of the
AP-1/Cx region were cloned into the BglII site of
pGL3A-TATA. The mutations described in the Figure 5 legend were
introduced into partially complementary synthetic oligonucleotides that
were extended by Klenow polymerase and then cloned into the
XbaI and XmaI sites of the 386 bp GAP-43
promoter. The mutations used to disrupt the GAP-43 repressive element
have already been described (Weber and Skene, 1997 ). Promoter
constructs made by PCR or synthesized DNA were confirmed by DNA
sequencing.
Cell cultures and transfections. Primary cultures of
dissociated rat cerebral cortex from embryonic day 18 were produced and cultured as described previously (Weber and Skene, 1997 ). Three days
after plating, the cortical cultures were treated with 5 µM arabinose C for 24 hr to kill the majority of
proliferating cells. HTC hepatoma cells (Thompson et al., 1966 ), RAT2
fibroblast-like cells (Topp, 1981 ), B1.1 Schwannoma cells (Anton et
al., 1995 ), C6 glioma cells (Benda et al., 1968 ), PC12 chromaffin-like
cells (Greene and Tischler, 1976 ), and CAD cells, a CNS
catecholaminergic neuronal cell line (Qi et al., 1997 ), were all
cultured and transfected with lipofectin reagent (Life Technologies,
Gaithersburg, MD) as described previously (Weber and Skene, 1997 ).
Cultures were harvested 2 d after transfection with 250 µl of
Promega reporter lysis buffer (catalog #E397A; Promega, Madison,
WI).
Luciferase and chloramphenicol acetyltransferase assays.
Luciferase assays were conducted with a Turner luminometer (Promega) and either the Promega luciferase assay system (catalog #E1500) and 20 µl of cell lysate or 50 µl cell lysate, 180 µl of assay buffer
(Brasier and Fortin, 1995 ), and injection of 100 µl of 2 mM luciferin. Promoter activity for each construct was
determined using duplicate plates and a minimum of three independent
experiments. The promoterless luciferase construct pGL3A-Basic was
included in every experiment so that the minor luciferase signal driven by vector sequences could be subtracted from activity driven by promoter constructs. All promoter-luciferase constructs were
cotransfected with a plasmid containing the Rous sarcoma virus promoter
and the gene for chloramphenicol acetyltransferase (CAT) (Gorman et al., 1982 ). CAT enzyme activity, measured using tritiated acetate (Nordeen et al., 1987 ), was used to monitor transfection efficiency for
each cell culture dish, and luciferase activity was normalized to the
CAT activity. To compare promoter activities between cell types,
luciferase expression for each promoter construct was normalized to a
modified version of the adenovirus E1b promoter that has a deletion of
a single G residue upstream of the TATA box (GGGGCGGGGC to
GGGGCGGGC). This control promoter has a similar signal-to-noise ratio
in neurons and hepatoma cells (8:1 and 9:1, respectively), but is
approximately eightfold less active than the wild-type E1b promoter.
Two other viral promoters were also tested with the luciferase reporter
gene in both neurons and hepatoma cells. The herpes simplex virus
thymidine kinase promoter had signal-to-noise ratio of 58:1 and 100:1
in neurons and hepatoma cells, respectively, and the Rous sarcoma virus
promoter had signal-to-noise ratios of 2600:1 and 1800:1 in neurons and
hepatoma cells, respectively. The observation that three different
viral promoters expressed well in both cell types indicates that the
strong preference for expression in neurons of the GAP-43 promoter is
unlikely to be attributable to a poor transfection efficiency in
hepatoma cells.
Protein extracts and electrophoretic mobility shift assays.
Nuclear extracts from postnatal day 5 rat cerebral cortex or liver were
prepared using the method of Gorski and coworkers (1986) . The nuclear
extracts were dialyzed against 25 mM HEPES, pH 7.9, 100 mM KCl, 0.1 mM EDTA, 10% glycerol, 0.1 mM phenylmethylsulfonal fluoride, and 1 mM
dithiothreitol. Small scale whole-cell or nuclear extracts from cell
cultures were made by the method of Dent and Latchman (1994) . Total
protein for all extracts was quantitated according to the Bradford
method (Smith, 1987 ).
Electrophoretic mobility shift assays (EMSAs) were conducted using 5%
polyacrylamide (29:1 ratio of acrylamide to bis-acrylamide) gels in low
ionic strength buffer (Chodosh, 1988 ). Oligonucleotide probes were
prepared and labeled with 32P as described previously
(Weber and Skene, 1997 ). The unique identity of the rat repressive
element probe, frog repressive element probe, rat AP-1 probe, and frog
AP-1 probe of Figure 9 were confirmed by restriction digest with
XbaI, Nci I, AluI, and HinfI restriction enzymes, respectively. Binding reactions
were conducted for 60 min on ice using 20,000-50,000 cpm of
radiolabeled probe (~0.1-0.4 ng DNA), 2 µg poly(dI-dC), 15 mM HEPES, pH 7.9, 60 mM KCl, 12% glycerol, 1 mM EDTA, and 1 mM dithiothreitol in a reaction
volume of 50 µl. The binding reactions used 15 ug of nuclear extracts
from postnatal cerebral cortex, 10 ug of liver nuclear extract, or
35-60 µg of whole-cell extracts. Under our conditions, the strongest
bands were achieved with 6 mM MgCl2 for AP-1 or
Liv1, 1 mM MgCl2 for repressive element
binding, and no MgCl2 for Cx1 and Cx2. Samples were loaded
directly onto gels and run at 45 mA for ~1 hr in a 4°C room. The
gels were dried and then exposed to film overnight at 80°C with an
intensifying screen.
 |
RESULTS |
Identification of an activator region downstream of the GAP-43
TATA box
We have demonstrated previously that a 386 bp rat GAP-43 promoter
has a strong preference for expression in neurons (Nedivi et al.,
1992 ), primarily because of a repressive element that blocks promoter
activity in non-neuronal cells (Weber and Skene, 1997 ). To identify and
characterize additional cis-acting elements involved in the
regulation of this promoter, we screened several subfragments of the
386 bp region for the ability to drive the expression of a luciferase
reporter gene in transfected cell cultures (Fig.
1). Deletion of 70 bp from the
promoter's 3' end (to obtain the 316 bp construct of Fig.
1A) results in a nearly fivefold loss of promoter
activity in primary cultures of neurons from developing rat cerebral
cortex. Deletion of an additional 20 bp, which includes an AP-1
consensus sequence (Eggen et al., 1994 ), produces a 296 bp promoter
with <10% of the activity of the original 386 bp promoter. This
dramatic loss of activity indicates that the 90 bp region spanned by
these deletions contains one or more positive-acting elements required
for maximal promoter activity in neurons.

View larger version (15K):
[in this window]
[in a new window]
|
Figure 1.
The activity of a neuron-specific 386 bp GAP-43
promoter depends on a synergy between a core promoter and a downstream
activator region. The rat GAP-43 promoter constructs shown
schematically were tested for the ability to drive the expression of a
luciferase reporter gene (Luc) in primary neuronal cultures or hepatoma
cells. The effect of deletions from the promoter's 3' end are shown in
A, whereas a demonstration of the synergistic effect
between the activator region and the core promoter is shown in
B. Luciferase activity for each construct is normalized
to the activity of a modified adenovirus promoter (see Materials and
Methods). SEMs are based on at least three experiments. The neuronal
cultures are dissociated cells from rat embryonic cerebral cortex
treated with an antimitotic agent to kill the majority of non-neuronal
cells. CCAAT, TATA, and
AP-1 consensus sequences are labeled. The bent
arrow designates the most 5' transcription start site, which is
located ~45 bp downstream of the TATA box (Nedivi et al., 1992 ;
Ortoft et al., 1993 ). The RNase protection assays performed by Ortoft
and coworkers (1993) on human transcripts indicate that there are more
dominant transcription start sites located ~70 and 100 bp downstream
of the TATA box (the transcription start sites for the rat promoter are
very likely to be the same as for human, because the rat and human
promoter sequences are highly conserved in this region). The 96 bp
sequence that we refer to as the core promoter includes sequences from
6 bp upstream of the CCAAT boxes to 59 bp downstream of the TATA box.
The 90 bp activator region includes the AP-1 consensus sequence.
|
|
On its own, this 90 bp putative activator region is able to drive only
a low level of reporter gene expression (Fig. 1B). Strong promoter activity in neurons requires both the activator region
and a core promoter, which contains CCAAT and TATA boxes that have been
shown previously to be required for promoter activity (Weber and Skene,
1997 ). The synergistic interaction between the activator and the core
promoter could be attributable to positive-acting transcription factors
that bind to sequences in the activator region. However, the ability of
the activator region to boost reporter gene expression also could be
explained by the presence of multiple transcription start sites in this
region (Ortoft et al., 1993 ) or by post-transcriptional effects,
because the activator region is located downstream of the TATA box and
the sense strand sequence of this region is transcribed into mRNA.
To investigate the mechanism by which the activator exerts its effects,
we placed this region upstream of a heterologous, viral TATA box (Fig.
2). In this context, a single copy of the activator region could elicit limited promoter activity, whereas two
copies of the activator elicited much stronger promoter activity. The
effects of the activator region were orientation dependent. When placed
in the forward orientation, as either one or two copies, the activator
region expressed five times more strongly in neurons than hepatoma
cells. When placed in the reverse orientation, activity in hepatoma
cells increased, whereas activity in neurons decreased (Fig. 2).

View larger version (12K):
[in this window]
[in a new window]
|
Figure 2.
The activator region is likely to contain
transcription factor binding sites. The activator region that was
defined in the previous figure was placed upstream of a TATA box and
transcription start site that were borrowed from the adenovirus E1b
promoter. As indicated in the schematics, the activator region was
inserted as one or two copies in either the forward or reverse
orientation. Promoter activity in neurons and hepatoma cells is
reported in the graph (same as Fig. 1).
|
|
The activator region used in these constructs does not include the
tissue-specific repressive element that accounts for the majority of
the neuronal specificity of the 386 bp GAP-43 promoter (Weber and
Skene, 1997 ). Therefore, the stronger activity in neurons, when the
activator was tested in the forward orientation, suggests that the
activator region may contain an additional element(s) that contributes
to the tissue specificity of the GAP-43 promoter. The observation that
two copies of the activator placed in reverse can still drive a
substantial level of reporter gene expression indicates that the
activator can stimulate transcription, because the ability of this
region to act upstream of a TATA box, and in the reverse orientation,
cannot be explained by post-transcriptional mechanisms mediated by the
presence of activator sequences in the mRNA transcript.
Identification of protein binding sites in the
activator region
To identify potential transcription factor binding sites in the
activator region, we tested small fragments of this sequence (Fig.
3A) for the ability to bind
proteins in EMSAs. Nuclear extract from postnatal rat cerebral cortex,
where endogenous GAP-43 expression is high, contains several binding
activities that recognize a small radiolabeled probe that includes the
AP-1 consensus sequence (Fig. 3B). Competition experiments
using unlabeled wild-type or mutated probes demonstrated that two of
these binding activities are clearly dependent on the AP-1 sequence.
Liver nuclear extracts contain a binding complex of exactly the same
mobility as one of the AP-1 binding activities from cerebral cortex
(Fig. 3C). Mutation of the AP-1 site slightly, but
reproducibly, diminished the ability of an unlabeled probe to compete
for the liver AP-1 binding activity. For both cortical and liver
nuclear extracts, there were additional binding activities that do not
appear to be dependent on the AP-1 sequence (Fig.
3B,C).

View larger version (88K):
[in this window]
[in a new window]
|
Figure 3.
Identification of protein binding sites in the
AP-1/Cx activator region. A, The DNA sequences used to
make probes for EMSAs are indicated by bars below the
sequence for the first 60 bp of the 90 bp AP-1/Cx activator region. The
AP-1 consensus sequence is boxed, and mutations
introduced into the probes are shown in lower case
letters. The sequence alteration used to mutate the AP-1 site
(TGACTAA to GTACTAA on the antisense strand)
has been demonstrated previously to disrupt AP-1 binding and activity
in another promoter (Lee et al., 1991 ). The location of novel putative
transcription factor binding sites are indicated by bars
labeled as Cx1, Liv1, and Cx2.
B, EMSAs with radiolabeled probe A and nuclear extract
from postnatal day 5 rat cerebral cortex. The first lane contains only
the radiolabeled probe and nuclear extract, whereas the additional
lanes include either a 100- or 500-fold molar excess of unlabeled
wild-type probe A or probe A with mutations 1, 2, or the combination of
mutations 1 and 2. P stands for a polylinker DNA with no
similarity to the probe A sequence. If a mutation affects protein
binding, then the competitor with that mutation should compete less
effectively or not at all. AP-1 specific-bands are labeled with
large arrows, and smaller arrows indicate
additional sequence specific bands that do not appear to depend on the
AP-1 sequence. C, EMSAs with probe A and liver nuclear
extract. D, EMSAs with probe B and nuclear extract from
postnatal cerebral cortex. Numbers designate probe B
with mutations 2, 3, 4, 5, or 6. Competitor probes were used at a
500-fold molar excess. Cx1 refers to the binding site defined by
mutations 2 and 3, whereas Cx2 refers to the binding site defined by
mutations 5 and 6. E, EMSAs with probe B and liver
nuclear extract. Competitors were used at a 50-fold molar excess in
this case. Liv1 refers to the binding site defined by mutations 3, 4, and 5.
|
|
To identify additional protein binding sites in the activator region,
we tested a second small radiolabeled probe corresponding to a portion
of the activator region downstream of the AP-1 consensus sequence (Fig.
3A, Probe B). This probe is recognized by two
distinct protein complexes present in nuclear extracts from postnatal
cerebral cortex. We refer to these binding activities as Cx1 and Cx2,
because they were detected in nuclear extracts from cerebral cortex
(Fig. 3D) but not from liver (Fig. 3E).
Competition with unlabeled oligonucleotides containing a series of
small (3 bp) mutations showed that Cx1 and Cx2 recognize distinct
sequences within Probe B (Fig. 3D). EMSAs with liver
extracts revealed an additional protein complex not detected in
cortical extracts. This third binding activity, which we name Liv1,
recognizes a DNA sequence that overlaps the Cx1 and Cx2 binding sites.
The striking difference in protein binding patterns between cortical
and liver nuclear extracts suggests that the region immediately
downstream of the AP-1 site could contribute to the neuron-specific
activity of the GAP-43 promoter.
Because our functional promoter assays are done by transient
transfection of cell cultures, we repeated the EMSA experiments using
protein extracts from cells cultured under the same conditions as for
our promoter assays. Very strong AP-1-specific binding of the same
electrophoretic mobility was detected in both the neuronal and hepatoma
cell cultures (Fig. 4). When the probe
for sequences downstream of the AP-1 site was used with neuronal
extracts, Cx1 binding was detected, but not Cx2 (data not shown). The
inability to detect Cx2 could be because of either its absence in the
neuronal cultures or perhaps some difference in the procedures for
preparing protein extracts from cell cultures rather than cerebral
cortex. The Liv1-specific binding detected with liver extracts was also detected with hepatoma protein extracts (data not shown).

View larger version (55K):
[in this window]
[in a new window]
|
Figure 4.
AP-1-specific binding in protein extracts from
neuronal and hepatoma cultures. A, EMSAs with probe A of
Figure 3 and whole-cell extract from cultures of embryonic rat cerebral
cortex. B, Same as A except with
whole-cell extracts from hepatoma cell cultures. Nuclear extracts from
the neuronal and hepatoma cell cultures gave similar results (data not
shown).
|
|
Taken together, the EMSA experiments indicate that the GAP-43 gene's
AP-1 site can be recognized in both neuronal and non-neuronal cells,
but that protein binding sites downstream of the AP-1 site may be used
quite differently in neurons and non-neuronal cells. It should also be
noted, however, that there might be some tissue-specific differences in
what versions of the AP-1 transcription factor preferentially bind the
AP-1 site and are best able to interact with other transcription
factors involved in the regulation of the GAP-43 gene.
Identification of positive-acting elements in the
activator region
To determine whether the protein binding sites identified by EMSAs
are important for the activity of the 386 bp GAP-43 promoter in
neurons, we modified the promoter with the same small mutations that
disrupted protein binding to the AP-1, Cx1, and Cx2 sites (Fig.
5). Combined mutation of the Cx1 and Cx2
sites reduced promoter activity in transfected neurons by more than
twofold. Mutation of the AP-1 consensus sequence resulted in a similar
loss of activity. A combination of mutations in the AP-1, Cx1, and Cx2
sites abolished the majority of the GAP-43 promoter's activity in
neurons (Fig. 5). However, the remaining neuron-specific activity is
still higher than when this entire region was deleted (Fig.
1A, 296 bp), indicating that there may
still be additional cis-acting elements in this activator
region.

View larger version (11K):
[in this window]
[in a new window]
|
Figure 5.
Transcription factor binding sites in the AP-1/Cx
activator region are required for the majority of the activity of the
386 bp GAP-43 promoter. Promoter constructs with mutations in proposed
transcription factor binding sites (AP-1, Cx1, Cx2) were tested for the
ability to drive expression of a reporter gene in neurons and hepatoma
cells (same as Fig. 1). The AP-1, Cx1, and Cx2 binding sites were
altered by using mutations 1, 2, and 6, respectively, of Figure
3.
|
|
Because the AP-1 and Cx sites are located downstream of the TATA box,
the loss of activity caused by mutations in these sites could result
from post-transcriptional effects attributable to an altered mRNA
sequence or perturbation of transcription start sites. However, the
observation that the same small mutations that reduce promoter activity
also cause a loss of protein binding is more consistent with the
proposal that this region contains a cluster of positive-acting
transcription factor binding sites. We have designated this region,
which is required for the activity of the 386 bp promoter in neurons,
as the AP-1/Cx region.
Evaluation of the tissue specificity of the AP-1/Cx
activator region
Mutational analysis demonstrates that the AP-1 site activates the
386 bp GAP-43 promoter in neurons but not in hepatoma cells (Fig. 5),
yet EMSA assays detected very robust AP-1 binding activity in hepatoma
cell extracts (Fig. 4B), suggesting that some
additional factor(s) prevents or counteracts the actions of AP-1 on the
GAP-43 promoter. We have shown previously that the majority of the
tissue specificity of the 386 bp GAP-43 promoter can be accounted for by a repressive element located between the TATA box and the AP-1/Cx activator region (Weber and Skene, 1997 ). Mutations in this repressive element result in a 3-fold to 10-fold increase in promoter activity in
various non-neuronal cells. Figure 6
shows that this activation of the 386 bp promoter in non-neuronal cells
is dependent on the AP-1 site, indicating that the AP-1 motif in the
GAP-43 promoter can be recognized by positive-acting AP-1 factors in
many different cell types. The five non-neuronal cell lines used (naive
PC12 cells, a chromaffin cell-derived line; B1.1, Schwannoma cells; C6,
glioma cells; HTC, hepatoma cells; RAT2, fibroblast-like cell line)
were chosen for their lack of endogenous GAP-43 expression. The three
neural but non-neuronal cell lines (PC12, B1.1, C6) may express low
levels of endogenous GAP-43, but under our culture conditions we
detected GAP-43 protein only in the primary cortical neuronal cultures
and the CAD neuronal cell line (Weber and Skene, 1997 ).

View larger version (33K):
[in this window]
[in a new window]
|
Figure 6.
Evaluation of the activity of the AP-1/Cx
activator region in a wide range of cell types. We have shown
previously that mutation of a repressive element located downstream of
the TATA box of the 386 bp GAP-43 promoter results in an increase in
promoter activity in non-neuronal cells (Weber and Skene, 1997 ). Here
we compare the activity of the wild-type 386 bp GAP-43 promoter, the
GAP-43 promoter with mutations in the previously characterized
repressive element, and the GAP-43 promoter with mutations in both the
repressive element and the AP-1 site (same AP-1 mutation as Fig. 3).
These promoter-reporter gene constructs were tested for activity in
primary neuronal cultures (Cx for neuronal cultures from rat embryonic
cerebral cortex), a neuronal cell line with high levels of endogenous
GAP-43 (CAD cells), and five non-neuronal cell lines: PC12, B1.1, C6,
HTC, and RAT2 (discussed in Results). Note that in each of the
non-neuronal cell types, mutation of the AP-1 site eliminates most or
all of the activity that had been achieved by disruption of the
repressive element.
|
|
In each of the non-neuronal cell types tested, mutation of the AP-1
site, in the context of a GAP-43 promoter in which the repressive
element had already been eliminated, resulted in a loss of activity
nearly equal in magnitude to the activity that had been gained by
mutation of the repressive element. This comparison indicates that the
AP-1 element is capable of driving GAP-43 promoter activity in
non-neuronal cells but is normally prevented from doing so by the
tissue-specific GAP-43 repressive element.
We used the same cell culture systems to evaluate the functional
contribution of the protein binding sites located immediately downstream of the AP-1 site. A mutation in the Liv1 binding site (Fig.
3, mutation 4) appeared to have no effect in our assay systems, even
when combined with the repressive element mutations (data not shown).
Mutation of the Cx1 and Cx2 sites in the context of the GAP-43 promoter
already had the repressive element mutations resulted in an
approximately twofold loss of activity in primary neuronal cultures
from rat embryonic cerebral cortex (Cx) (Fig. 7). However, these
mutations did not result in a loss of activity in a neuronal cell line
(CAD cells, a CNS catecholaminergic cell line) (Qi et al., 1997 ) or in
any of the five non-neuronal cell lines tested. Thus, in contrast to
the AP-1 element, the Cx1 and/or Cx2 site(s) do not appear to be
activated in non-neuronal cells and so do not depend on the GAP-43
repressive element to restrict their activity to neurons. The
contribution of the Cx elements to neuron-specific promoter activity
appears to differ among different populations of neurons, which may
reflect differences in subtypes of neurons or other differences between
primary cortical cultures and immortalized CAD cells.
Comparison of mammalian and amphibian promoter sequences
The 386 bp GAP-43 promoter from rat is preferentially expressed in
the developing nervous system of transgenic zebrafish, indicating that
one or more of the cis-acting elements that regulate this
promoter must be highly conserved among vertebrates (Reinhard et al.,
1994 ). To identify phylogenetically conserved cis-regulatory elements in this promoter, we compared sequences from the corresponding regions of the human, rat, and frog GAP-43 genes (Fig.
8). In the
region encompassing the CCAAT and TATA boxes, there is a 78 bp stretch
of human sequence that is absolutely identical to the rat sequence, and
the equivalent amphibian sequence is >80% identical. This high degree
of sequence conservation suggests that the functional role of these
elements is likely to be critical for proper regulation of the GAP-43
gene.

View larger version (35K):
[in this window]
[in a new window]
|
Figure 7.
The Cx1 and Cx2 sites contribute to
neuron-specific expression of the GAP-43 promoter. The 386 bp GAP-43
promoter with mutations in the repressive element is compared with the
same promoter with additional mutations in the Cx1 and Cx2 sites (same
methods as in Fig. 6).
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Figure 8.
Comparison of mammalian and amphibian GAP-43
sequences. Human (Ortoft et al., 1993 ), rat (GenBank accession number
M88356; Nedivi et al., 1992 ), and Xenopus (GenBank
accession number Y09834; submitted by L. H. Schrama, Rudolf Magnus
Institute for Neuroscience, Utrecht, The Netherlands) GAP-43 sequences
surrounding and downstream of the GAP-43 TATA box are shown. The human
and frog sequences are reported only where they deviate from the rat
sequence in our alignment. A dash indicates a space
inserted to obtain the best alignment. Conservation of the boxed
elements is discussed in Results, and consensus sequences that
should be read on the complementary strand are marked as reverse
(rev).
|
|
The GAP-43 AP-1 site also appears to be phylogenetically conserved. In
the alignment shown in Figure 8, the human and rat genes have the same
AP-1 sequence, but the corresponding frog sequence deviates by 2 bp.
However, this frog sequence (TGACTCC as read on the antisense strand)
has been identified as an AP-1 site in the promoter of the rat JE gene
(Timmers et al., 1990 ) and its homolog the human monocyte chemotactic
protein 1 (MCP-1) gene (Shyy et al., 1995 ). These sequence comparisons
suggest that the frog GAP-43 gene is likely to have an AP-1 binding
site in the same location, relative to the TATA box, as the rat and
human genes.
Downstream of the AP-1 site, the human and frog sequences have no
obvious similarities to the rat Cx2 binding site defined in Figure 3.
The Cx1 binding site, however, is likely to be present in the human
sequence, because the rat and human sequences have 12 identical bp
within a 13 bp region spanning the Cx1 site. It is less obvious whether
there is a Cx1 site in the frog sequence. At the corresponding location
in the frog, only 8 of the 13 bp are identical to the rat sequence, and
we have not determined whether this similarity is sufficient to allow
binding of either the mammalian Cx1 factor or any corresponding protein
from frog.
In the region of the GAP-43 repressive element, the human sequence is
nearly identical to that of the rat, whereas the frog sequence deviates
enough to suggest that only one of the two factors that bind to the rat
sequence is likely to also bind to the frog sequence. We found
previously that this region of the rat GAP-43 gene is recognized by at
least two distinct protein factors. One of these factors recognizes a
single site of ~9 bp and also binds to sequences found downstream of
the 25 kDa synaptosome-associated protein (SNAP-25) and neuronal nitric
oxide synthase (nNOS) gene's TATA boxes, allowing us to derive the
SNOG consensus sequence (A/G)ATG(A/G)GGG(C/T) (Weber and Skene, 1997 ).
The rat and human promoters both contain this sequence (Fig. 8, site
C), but the frog sequence varies enough from the consensus
that it is unclear whether the SNOG element is conserved between
amphibians and mammals.
A second factor that recognizes the rat GAP-43 repressive element binds
to a much larger site that includes sequences in both site A and site C
of Figure 8 (Weber and Skene, 1997 ). Site A corresponds to a consensus
binding sequence for members of the NGFI-A/EGR family of transcription
factors. The equivalent frog sequence varies from the 9 bp rat site A
sequence by an adenosine instead of a guanosine in the fifth position
and an adenosine instead of a cytidine in the eighth position.
Intriguingly, a study using recombinant members of the NGFI-A/EGR
family of transcription factors to select random DNA sequences has
demonstrated that there is a considerable degree of variability in the
DNA sequences to which these proteins bind (Swirnoff and Milbrandt,
1995 ), and both the rat and frog site A fit the experimentally derived
NGFI-A/EGR consensus sequence. Although the originally described
binding sequence for this family was GCGGGGGCG, the selection
experiments showed that some members of the family would choose an
adenosine in the second or eighth position ~5-10% of the time and
an adenosine in the fifth position anywhere from 24 to 31% of the
time.
Binding by the factor that recognizes the NGFI-A/EGR-like sequence
(site A) also requires a second sequence (site C) that overlaps the
SNOG element (Weber and Skene, 1997 ). Similarity between the rat and
frog sequences in the general region of site C is less obvious, but
both the rat and frog sequences have a conserved thymidine that is
surrounded by several purines on either side. Taking into account that
very large binding sites can accommodate a substantial amount of
variability in the sequences to which they will bind (Schoenherr et
al., 1996 ), the sequence similarities in site A and the general region
of site C suggest that the frog gene is likely to have a binding site
for at least one of the factors that recognizes the rat GAP-43
repressive element and that this binding site is located the same
distance downstream of the TATA box in human, rat, and frog genes.
Binding of mammalian proteins to frog GAP-43
promoter sequences
To determine whether any of the mammalian proteins that bind the
rat GAP-43 repressive element can actually bind to similar sequences in
the frog gene, the rat and frog repressive element probes shown in
Figure 9A were used as
competitors in EMSAs. The sequence-specific bands obtained with
hepatoma extracts and the frog repressive element (Fig. 9B)
had the same mobilities as the complexes we observed previously with
the rat GAP-43 repressive element (Weber and Skene, 1997 ), except that
we did not detect a band of the same mobility as the complex that bound
to only the SNOG consensus. Unlabeled rat and frog repressive elements competed about equally well for the radiolabeled probe. Moreover, a
combination of mutations in both site A and site C of the rat repressive element were required to fully disrupt its ability to
compete for the frog repressive element.

View larger version (51K):
[in this window]
[in a new window]
|
Figure 9.
Mammalian proteins bind to a potential frog GAP-43
repressive element and AP-1 site. A, Rat and frog
repressive element probes for EMSAs are shown with
brackets enclosing an NGFI-A/EGR consensus sequence
(Fig. 8, site A) and a purine-rich sequence that overlaps with site C
of Figure 8. Sequences in the frog AP-1 probe that are similar to the
bracketed regions of the repressive element probes are bracketed and
discussed in Results. The AP-1 consensus sequence is
boxed and should be read on the strand complementary to
the sequence shown. Mutations in the EMSA probes are shown in
lower case letters, and the wild-type sequences they
replace are overlined or underlined.
B, EMSAs with hepatoma whole-cell extracts and
radiolabeled frog repressive element probe. Competitor probes were used
at a 200-fold molar excess relative to the radiolabeled probe. The
hollow arrow marks the relative mobility of the SNOG
element-specific band that binds to the rat repressive element, as we
have shown previously (Weber and Skene, 1997 ), but an equivalent band
was not obtained with the frog repressive element. The SNAP-25 SNOG
competitor probe contains a high-affinity binding site for the SNOG
element, but does not contain an NGFI-A/EGR consensus sequence.
C, EMSAs with radiolabeled frog AP-1 probe and hepatoma
whole-cell extracts. The sequence of the rat AP-1 competitor probe is
given in Figure 3A. Note that repressive
element-specific rather than AP-1-specific bands were obtained (see
Results and Discussion). We verified the identity of each of the probes
in question (see Materials and Methods) and conducted several repeat
experiments to confirm these unexpected results. An independently
synthesized batch of the frog AP-1 probe yielded the same results.
D, Same as C except that the radiolabeled
frog AP-1 probe contains mutations mA and mC and the magnesium
concentration has been optimized to 6 mM rather than 1 mM (see Materials and Methods). When the EMSA in
C was conducted at 6 mM magnesium rather
than 1 mM, the repressive element binding was less intense,
but we still could not detect any AP-1-specific bands (data not shown).
Competitors were used at a 50-fold or 250-fold excess relative to the
radiolabeled probe.
|
|
Quite surprisingly, a DNA probe spanning the frog AP-1 site was a
highly effective competitor for the radiolabeled frog (Fig. 9B) or rat (data not shown) repressive element. Moreover,
the radiolabeled frog AP-1 probe produced bands of the same mobility as
the repressive element probe (Fig. 9C). The rat AP-1 probe does not compete for these bands, but the frog and rat repressive element probes do (Fig. 9C).
Careful comparison of the frog AP-1 probe sequence with the frog
and rat repressive elements provides an explanation for this unexpected
binding pattern (Fig. 9A). Our mutational analysis indicated
that the GAP-43 repressive element comprises two parts: site A, which
fits the NGFI-A/EGR consensus sequence, and a highly purine-rich site
C. The rat and frog site A define a consensus sequence of
GAGG(A/G)GGG(A/C)G. Overlapping the frog AP-1 site is a sequence that
varies from this site A consensus by only one base. Downstream of site
A, the rat and frog repressive elements share a conserved thymidine
flanked by five purines on either side. The equivalent sequences in the
vicinity of the frog AP-1 site also have a thymidine in the middle of a
purine-rich sequence. These sequence comparisons, along with our EMSA
results, indicate that the frog GAP-43 gene contains two complete
copies of one of the protein binding sites found in the rat GAP-43
repressive element.
Although the frog AP-1 probe clearly bound one of the factors that
recognizes the GAP-43 repressive element, it showed no binding mediated
by the AP-1 consensus (Fig. 9C). The apparent lack of
AP-1-specific binding could be attributable to interference by the
factor that binds to the repressive element-like sequence that overlaps
the frog AP-1 site. To eliminate this potential interference, we made a
frog AP-1 probe in which the sequences surrounding the AP-1 site were
disrupted (Fig. 9A, mutations A and C). With this new probe,
we detected a band of the same mobility as had been obtained with the
rat AP-1 probe in Figure 4B (Fig. 9D). The
frog AP-1 sequence, which varies by 2 bp from the equivalent rat
sequence, is bound only weakly by the mammalian proteins that had
produced very robust binding to the rat GAP-43 AP-1 site. However, this
binding is AP-1 specific, because the rat AP-1 probe was an extremely
effective competitor, and mutation of the frog AP-1 site eliminated its
ability to compete.
These binding assays indicate that mammalian proteins can recognize at
least some of the frog GAP-43 sequences. The frog gene contains two
complete copies of the binding site for one of the factors that
recognizes the rat GAP-43 repressive element, and the second copy can
interfere with binding to the AP-1 site that it overlaps.
 |
DISCUSSION |
Neuron-specific gene transcription can be accomplished by a
combination of positive and negative methods
Tissue-specific gene transcription can be achieved by two
basic methods: (1) the use of positive-acting DNA elements that are
recognized by transcription factors present in certain cell types, but
not others, and (2) the use of negative-acting DNA elements to prevent
transcription, in inappropriate cell types, that would otherwise be
driven by widely recognized positive-acting DNA elements. As an example
of the first method, binding sites for Pit-1, a transcription factor
that is restricted to cells of the pituitary gland in adults, play a
key role in determining the pituitary-specific expression of the growth
hormone and prolactin genes (Lefevre et al., 1987 ; Nelson et al., 1988 ;
Ingraham et al., 1990 ). A good example of the second method is the
repressive element 1/neuron-restrictive silencer element (RE1/NRSE),
which binds a factor, the RE1-silencing transcription
factor/neuron-restrictive silencer factor (REST/NRSF), that prevents
transcription from the type II sodium channel and SCG10 promoters in
non-neural cells (Kraner et al., 1992 ; Mori et al., 1992 ; Chong et al.,
1995 ; Schoenherr and Anderson, 1995a ,b ).
The 386 bp GAP-43 promoter we have studied here uses both methods for
achieving neuron-specific expression. Two novel transcription factor
binding sites, Cx1 and Cx2, boost promoter activity in neuronal
cultures from embryonic rat cerebral cortex, but not in any of several
other cell types that we tested. The majority of the tissue specificity
of this promoter, however, is conferred by a repressive element located
downstream of the GAP-43 TATA box (Weber and Skene, 1997 ). We have now
shown that the GAP-43 repressive element, which is unrelated to the
RE1/NRSF element, is sufficient to block the activity in non-neuronal
cells that would otherwise be driven by a highly promiscuous AP-1
element. This strategy allows the GAP-43 gene to take advantage of a
signal transduction pathway(s) present in a wide range of tissue types yet still remain highly tissue specific.
Regulation of GAP-43 transcription by AP-1
AP-1 transcription factors are found in most cell types
and are activated in response to a fairly wide range of extracellular stimuli (Sheng and Greenberg, 1990 ; Herschman, 1991 ). The response of
individual genes to AP-1 activation depends on cell type and history
(Morgan and Curran, 1995 ), suggesting that transcription factors that
can cooperate or interfere with AP-1 driven activity are likely to be
important determinants of promoter specificity. The tissue-specific
GAP-43 repressive element should allow signaling events associated with
neuronal differentiation to use the AP-1 signaling pathway(s) without
the undesired side effect of activating GAP-43 transcription outside of
the nervous system. The repressive element may also play a role in
preventing AP-1 from causing overexpression of the GAP-43 gene in glial
cells. Primary cultures of Schwann cells that express endogenous GAP-43
fail to express a small GAP-43 promoter that includes the AP-1 site
(Plantinga et al., 1994 ), despite the fact that cultured Schwann cells
express high levels of c-Jun (De Felipe and Hunt, 1994 ).
Instead, transcriptional activity is driven by sequences immediately
adjacent to the GAP-43 protein coding region (a proposed 230 bp
TATA-less promoter).
Correlative evidence suggests that AP-1 transcription factors may
contribute to activation of the GAP-43 gene in neurons during axon
outgrowth. One of the components of AP-1, c-Jun, is highly elevated during axon regeneration by dorsal root ganglion neurons (Herdegen and Zimmermann, 1994 ; Schaden et al., 1994 ). Moreover, both
c-Jun (Herdegen and Zimmermann, 1994 ) and GAP-43 (Van der Zee et al., 1989 ; Schreyer and Skene, 1991 ) will remain elevated for
months if the regenerating axons are prevented from reinnervating their
target tissue. c-Jun and GAP-43 are also elevated in adult retinal ganglion cells under conditions conducive to axon regeneration (Herdegen and Zimmermann, 1994 ; Schaden et al., 1994 ).
If c-Jun is a positive regulator of the GAP-43 gene, it may
need to work in cooperation with other transcription factors, including
other members of the AP-1 family. Differences in the composition of
AP-1 can determine its binding affinity and which intracellular
signaling pathways it responds to (Hai and Curran, 1991 ; Kerppola and
Curran, 1994 ; Gass and Herdegen, 1995 ). Identification of the GAP-43
AP-1 site as a functional regulatory element opens up a new avenue for
determining what version(s) of AP-1 is involved in regulation of the
GAP-43 gene.
Regulation of GAP-43 transcription by Cx1 and Cx2
The Cx1 and/or Cx2 elements are important for activity in primary
neuronal cultures from embryonic rat cerebral cortex but are not used
in any of the non-neuronal cells we have tested. Under our culture
conditions, the Cx1 and Cx2 sites do not appear to be used in CAD
cells, although this murine CNS catecholaminergic neuronal cell line
has high levels of endogenous GAP-43 (Qi et al., 1997 ; Weber and Skene,
1997 ) and expresses the 386 bp GAP-43 promoter construct nearly as well
as the primary neuronal cultures. This differential use of the Cx1
and/or Cx2 elements could reflect differences in neuronal subtype.
Alternatively, these elements might be used only at certain stages of
neuronal differentiation or in response to specific signaling events
that differ between our two neuronal culture systems.
Phylogenetic conservation of cis-acting elements
proximal to the GAP-43 TATA box
The regulation of the endogenous GAP-43 gene involves many
additional regulatory elements outside of the small promoter region on
which we have focused here (Nedivi et al., 1992 ; Ortoft et al., 1993 ;
Perrone-Bizzozero et al., 1993 ; Eggen et al., 1994 ; Reinhard et al.,
1994 ; Vanselow et al., 1994 ; Weber and Skene, 1997 ). However, the high
degree of phylogenetic conservation (Groen et al., 1995 ) in this small
region indicates that many of the elements we have characterized are
likely to play a critical role in the regulation of the GAP-43 gene and
perhaps in other genes involved in neuronal differentiation and axon
outgrowth.
The neuron-specific activity of the 386 bp rat GAP-43 promoter is
determined by a combinatorial code involving both positive (Cx1 and
Cx2) and negative (the repressive element) tissue-specific elements and
an AP-1 site that can be recognized in a wide range of cell types.
Although we have not yet evaluated the novel Cx1 and Cx2 sites
separately, phylogenetic comparisons suggest that the Cx1 site is
likely to be the more important regulatory element. The rat Cx2
sequence is not present in the human or frog promoters, whereas the Cx1
site is conserved between rat and human promoters and has at least some
similarities between the rat and frog sequences.
The rat GAP-43 repressive element has binding sites for two different
factors. Binding by one of these factors depends only on the 9 bp SNOG
consensus sequence (G/A)ATG(G/A)GGG (C/T), which is also found in the
SNAP-25 and neuronal NOS genes (Weber and Skene, 1997 ). The second
factor that binds to the GAP-43 repressive element recognizes a
bipartite purine-rich (BIPPUR) element. The first part of this element
has a striking similarity to the consensus sequence for the NGFI-A/EGR
family of transcription factors (Swirnoff and Milbrandt, 1995 ). The
second part is a purine-rich sequence that overlaps the SNOG element in
the rat and human GAP-43 genes.
Although the Xenopus GAP-43 gene does not contain a SNOG
element, it does contain two complete copies of the BIPPUR element. The
second copy appears to be able to interfere with binding to the frog
AP-1 site. The ability of mammalian proteins to recognize these
amphibian BIPPUR elements strongly suggests that this element plays an
important phylogenetically conserved role in the regulation of the
GAP-43 gene.
We have not established a causal relationship between protein binding
and inhibition of transcription by the GAP-43 repressive element.
However, the factor that binds to the BIPPUR element is a good
candidate for a repressor, because its binding is well correlated with
transcriptional repression in non-neuronal cells (Weber and Skene,
1997 ). The functional role of the SNOG element is currently unclear.
However, identification of the BIPPUR and SNOG elements as
distinct components of the mammalian GAP-43 repressive element should facilitate the identification of these
elements in other neuronal genes and lead to a clarification of the
regulatory roles of the factors that bind these elements.
 |
FOOTNOTES |
Received Dec. 10, 1997; revised March 31, 1998; accepted May 5, 1998.
This work was supported by National Institutes of Health Grant EY07397.
The CAD cells were kindly provided by Dona Chikaraishi and Yanping Qi,
and the B1.1 Schwannoma cells were kindly provided by Bill Matthew.
Correspondence should be addressed to Pate Skene, Box 3209, Duke
University Medical Center, Durham, NC 27710.
Dr. Weber's present address: Beth Israel Deaconess Medical Center, 330 Brookline Avenue, RW663, Boston, MA 02215.
 |
REFERENCES |
-
Anchan RM,
Drake DP,
Haines CF,
Gerwe EA,
LaMantia AS
(1997)
Disruption of local retinoid-mediated gene expression accompanies abnormal development in the mammalian olfactory pathway.
J Comp Neurol
379:171-184[Web of Science][Medline].
-
Anton ES,
Hadjiargyrou M,
Patterson PH,
Matthew WD
(1995)
CD9 plays a role in Schwann cell migration in vitro.
J Neurosci
15:584-595[Abstract].
-
Bassuk AG,
Leiden JM
(1995)
A direct physical association between ETS and AP-1 transcription factors in normal human T cells.
Immunity
3:223-237[Web of Science][Medline].
-
Benda P,
Lightbody J,
Sato G,
Levine L,
Sweet W
(1968)
Differentiated rat glial cell strain in tissue culture.
Science
161:370-371[Abstract/Free Full Text].
-
Brasier AR,
Fortin JJ
(1995)
Nonisotopic assays for reporter gene activity.
In: Current protocols in molecular biology (Ausubel FM,
Brent R,
Kingston RE,
Moore DD,
Seidman JG,
Smith JA,
Struhl K,
eds), pp 9.7.12-9.7.14. New York: Wiley.
-
Chodosh LA
(1988)
Mobility shift DNA-binding assay using gel electrophoresis.
In: Current protocols in molecular biology (Ausubel FM,
Brent R,
Kingston RE,
Moore DD,
Seidman JG,
Smith JA,
Struhl K,
eds), pp 12.2.1-12.2.10. New York: Wiley.
-
Chong JA,
Tapia-Ramirez J,
Kim S,
Toledo-Aral JJ,
Zheng Y,
Boutros MC,
Altshuller YM,
Frohman MA,
Kraner SD,
Mandel G
(1995)
REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons.
Cell
80:949-957[Web of Science][Medline].
-
De Felipe C,
Hunt SP
(1994)
The differential control of c-Jun expression in regenerating sensory neurons and their associated glial cells.
J Neurosci
14:2911-2923[Abstract].
-
Deloulme JC,
Laeng P,
Janet T,
Sensenbrenner M,
Baudier J
(1993)
Expression of neuromodulin (GAP-43) and its regulation by basic fibroblast growth factor during the differentiation of O-2A progenitor cells.
J Neurosci Res
36:147-162[Web of Science][Medline].
-
Dent CL,
Latchman DS
(1994)
The DNA mobility shift assay.
In: Transcription factors (Latchman DS,
ed), pp 1-26. Oxford: Oxford UP.
-
Eggen BJL,
Nielander HB,
Rensen-de Leeuw MG,
Schotman P,
Gispen WH,
Schrama LH
(1994)
Identification of two promoter regions in the rat B-50/GAP-43 gene.
Mol Brain Res
23:221-234[Medline].
-
Gass P,
Herdegen T
(1995)
Neuronal expression of AP-1 proteins in excitotoxic-neurodegenerative disorders and following nerve fiber lesions.
Prog Neurobiol
47:257-290.
-
Gorman CM,
Merlino GT,
Willingham MC,
Pastan I,
Howard BH
(1982)
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.
Proc Natl Acad Sci USA
79:6777-6781[Abstract/Free Full Text].
-
Gorski K,
Carneiro M,
Schibler U
(1986)
Tissue-specific in vitro transcription from the mouse albumin promoter.
Cell
47:767-776[Web of Science][Medline].
-
Greene LA,
Tischler AS
(1976)
Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.
Proc Natl Acad Sci USA
73:2424-2428[Abstract/Free Full Text].
-
Groen PC,
Eggen BJL,
Gispen WH,
Schotman P,
Schrama LH
(1995)
Cloning and promoter analysis of the human B-50/GAP-43 gene.
J Mol Neurosci
6:109-119[Web of Science][Medline].
-
Hai T,
Curran T
(1991)
Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.
Proc Natl Acad Sci USA
88:3720-3724[Abstract/Free Full Text].
-
Herdegen T,
Zimmermann M
(1994)
Expression of c-Jun and JunD transcription factors represent specific changes in neuronal gene expression following axotomy.
Prog Brain Res
103:153-171[Web of Science][Medline].
-
Herdegen T,
Skene P,
Bahr M
(1997)
The c-Jun transcription factor: bipotential mediator of neuronal death, survival and regeneration.
Trends Neurosci
20:227-231[Web of Science][Medline].
-
Herschman HR
(1991)
Primary response genes induced by growth factors and tumor promoters.
Annu Rev Biochem
60:281-319[Web of Science][Medline].
-
Heuss D,
Engelhardt A,
Gobel H,
Neundorfer B
(1995)
Light-microscopic study of phosphoprotein B-50 in myopathies.
Virchows Arch
426:69-76[Web of Science][Medline].
-
Igarashi K,
Kataoka K,
Itoh K,
Hayashi N,
Nishizawa M,
Yamamoto M
(1994)
Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins.
Nature
367:568-572[Medline].
-
Ingraham HA,
Albert VR,
Chen RP,
Crenshaw EB,
Elsholtz HP,
He X,
Kapiloff MS,
Mangalam HJ,
Swanson LW,
Treacy MN,
Rosenfeld MG
(1990)
A family of POU-domain and Pit-1 tissue-specific transcription factors in pituitary and neuroendocrine development.
Annu Rev Physiol
52:773-791[Web of Science][Medline].
-
Jacobson RD,
Virag I,
Skene JHP
(1986)
A protein associated with axon growth, GAP-43, is widely distributed and developmentally regulated in rat CNS.
J Neurosci
6:1843-1855[Abstract].
-
Karin M,
Liu Z,
Zandi E
(1997)
AP-1 function and regulation.
Curr Opin Cell Biol
9:240-246[Web of Science][Medline].
-
Kerppola TK,
Curran T
(1994)
Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun.
Oncogene
9:675-684[Web of Science][Medline].
-
Kraner SD,
Chong JA,
Tsay HJ,
Mandel G
(1992)
Silencing the type II sodium channel gene: a model for neural-specific gene regulation.
Neuron
9:37-44[Web of Science][Medline].
-
Lee ME,
Dhadly MS,
Temizer DH,
Clifford JA,
Yoshizumi M,
Quertermous T
(1991)
Regulation of endothelin-1 gene expression by Fos and Jun.
J Biol Chem
266:19034-19039[Abstract/Free Full Text].
-
Lefevre C,
Imagawa M,
Dana S,
Grindlay J,
Bodner M,
Karin M
(1987)
Tissue-specific expression of the human growth hormone gene is conferred in part by the binding of a specific trans-acting factor.
EMBO J
6:971-981[Web of Science][Medline].
-
Morgan JI,
Curran T
(1995)
Immediate-early genes: ten years on.
Trends Neurosci
18:66-67[Web of Science][Medline].
-
Mori N,
Schoenherr C,
Vandenbergh DJ,
Anderson DJ
(1992)
A common silencer element in the SCG10 and type II Na+ channel genes binds a factor present in nonneuronal cells but not in neuronal cells.
Neuron
9:45-54[Web of Science][Medline].
-
Nedivi E,
Basi GS,
Virag-Akey I,
Skene JH
(1992)
A neural-specific GAP-43 core promoter located between unusual DNA elements that interact to regulate its activity.
J Neurosci
12:691-704[Abstract].
-
Nelson C,
Albert VR,
Elsholtz HP,
Lu LI,
Rosenfeld MG
(1988)
Activation of cell-specific expression of rat growth hormone and prolactin genes by a common transcription factor.
Science
239:1400-1405[Abstract/Free Full Text].
-
Nordeen SK,
Green PP,
Fowlkes DM
(1987)
A rapid, sensitive, and inexpensive assay for chloramphenicol acetyltransferase.
DNA
6:173-178[Web of Science][Medline].
-
Ortoft E,
Pahlman S,
Andersson G,
Parrow V,
Betsholtz C,
Hammerling U
(1993)
Human GAP-43 gene expression: multiple start sites for initiation of transcription in differentiating human neuroblastoma cells.
Mol Cell Neurosci
4:549-561.
-
Perrone-Bizzozero NI,
Cansino VV,
Kohn DT
(1993)
Post-transcriptional regulation of GAP-43 gene expression in PC12 cells through protein kinase C-dependent stabilization of the mRNA.
J Cell Biol
120:1263-1270[Abstract/Free Full Text].
-
Plantinga LC,
Verhaagen J,
Gispen WH
(1993)
The expression of B-50/GAP-43 in Schwann cells.
Ann NY Acad Sci
679:412-417[Web of Science][Medline].
-
Plantinga LC,
Schrama LH,
Eggen BJL,
Gispen WH,
Verhaagen J,
Lemke G
(1994)
B-50/GAP-43 mRNA expression in cultured primary Schwann cells is regulated by cyclic AMP.
NeuroReport
5:2465-2468.[Web of Science][Medline]
-
Qi Y,
Wang JKT,
McMillian M,
Chikaraishi DM
(1997)
Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation.
J Neurosci
17:1217-1225[Abstract/Free Full Text].
-
Reinhard E,
Nedivi E,
Wegner J,
Skene JH,
Westerfield M
(1994)
Neural selective activation and temporal regulation of a mammalian GAP-43 promoter in zebrafish.
Development
120:1767-1775[Abstract].
-
Schaden H,
Stuermer CA,
Bahr M
(1994)
GAP-43 immunoreactivity and axon regeneration in retinal ganglion cells of the rat.
J Neurobiol
25:1570-1578[Web of Science][Medline].
-
Schoenherr CJ,
Anderson DJ
(1995a)
The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes.
Science
267:1360-1363[Abstract/Free Full Text].
-
Schoenherr CJ,
Anderson DJ
(1995b)
Silencing is golden: negative regulation in the control of neuronal gene transcription.
Curr Opin Neurobiol
5:566-571[Web of Science][Medline].
-
Schoenherr CJ,
Paquette AJ,
Anderson DJ
(1996)
Identification of potential target genes for the neuron-restrictive silencer factor.
Proc Natl Acad Sci USA
93:9881-9886[Abstract/Free Full Text].
-
Schreyer DJ,
Skene JHP
(1991)
Fate of GAP-43 in ascending spinal axons of DRG neurons after peripheral nerve injury: delayed accumulation and correlation with regenerative potential.
J Neurosci
11:3738-3751[Abstract].
-
Sheng M,
Greenberg ME
(1990)
The regulation and function of c-fos and other immediate early genes in the nervous system.
Neuron
4:477-485[Web of Science][Medline].
-
Shyy JY-J,
Lin M-C,
Han J,
Lu Y,
Petrime M,
Chien S
(1995)
The cis-acting phorbol ester "12-O-tetradecanoylphorbol 13-acetate"-responsive element is involved in shear stress-induced monocyte chemotactic protein 1 gene expression.
Proc Natl Acad Sci USA
92:8069-8073[Abstract/Free Full Text].
-
Skene JHP
(1989)
Axonal growth-associated proteins.
Annu Rev Neurosci
12:127-156[Web of Science][Medline].
-
Skene JHP
(1992)
Retrograde pathways controlling expression of a major growth cone component in the adult CNS.
In: The nerve growth cone (Letourneau PC,
Kater SB,
Macagno ER,
eds), pp 463-465. New York: Raven.
-
Smith JA
(1987)
Quantitation of proteins.
In: Current protocols in molecular biology (Ausubel FM,
Brent R,
Kingston RE,
Moore DD,
Seidman JG,
Smith JA,
Struhl K,
eds), p 10.1.1. New York: Wiley.
-
Stocker KM,
Baizer L,
Ciment G
(1992)
Transient expression of GAP-43 in non-neuronal cells of the embryonic chicken limb.
Dev Biol
149:406-414[Web of Science][Medline].
-
Swirnoff AH,
Milbrandt J
(1995)
DNA-binding specificity of NGFI-A and related zinc finger transcription factors.
Mol Cell Biol
15:2275-2287[Abstract].
-
Thompson EB,
Tomkins GM,
Curran JF
(1966)
Induction of tyrosine alpha-ketoglutarate transaminase by steroid hormones in a newly established tissue culture cell line.
Proc Natl Acad Sci USA
56:296-303[Free Full Text].
-
Timmers HTM,
Pronk JG,
Bos JL,
van der Eb AJ
(1990)
Analysis of the rat JE gene promoter identifies an AP-1 binding site essential for basal expression but not for TPA induction.
Nucleic Acids Res
18:23-34[Abstract/Free Full Text].
-
Topp WC
(1981)
Normal rat cell lines deficient in nuclear thymidine kinase.
Virology
113:408-411[Web of Science][Medline].
-
Van der Zee CE,
Nielander HB,
Vos JP,
Lopes da Silva S,
Verhaagen J,
Oestreicher AB,
Schrama LH,
Schotman P,
Gispen WH
(1989)
Expression of growth-associated protein B-50 (GAP43) in dorsal root ganglia and sciatic nerve during regenerative sprouting.
J Neurosci
9:3505-3512[Abstract].
-
Vanselow J,
Grabczyk E,
Ping J,
Baetscher M,
Teng S,
Fishman MC
(1994)
GAP-43 transgenic mice: dispersed genomic sequences confer a GAP-43-like expression pattern during development and regeneration.
J Neurosci
14:499-510[Abstract].
-
Weber JRM,
Skene JHP
(1997)
Identification of a novel repressive element that contributes to neuron-specific gene expression.
J Neurosci
17:7583-7593[Abstract/Free Full Text].
-
Wu L,
Rosser DS,
Schmidt MC,
Berk A
(1987)
A TATA box implicated in E1A transcriptional activation of a simple adenovirus 2 promoter.
Nature
326:512-515[Medline].
Copyright © 1998 Society for Neuroscience 0270-6474/98/18145264-11$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
Q. Lu, Q. Cui, H. K. Yip, and K.-F. So
c-Jun Expression in Surviving and Regenerating Retinal Ganglion Cells: Effects of Intravitreal Neurotrophic Supply
Invest. Ophthalmol. Vis. Sci.,
December 1, 2003;
44(12):
5342 - 5348.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Coleman, G. E. Fuchs, and S. L. Semple-Rowland
Analyses of the Guanylate Cyclase Activating Protein-1 Gene Promoter in the Developing Retina
Invest. Ophthalmol. Vis. Sci.,
May 1, 2002;
43(5):
1335 - 1343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Udvadia, R. Koster, and J. Skene
GAP-43 promoter elements in transgenic zebrafish reveal a difference in signals for axon growth during CNS development and regeneration
Development,
January 4, 2001;
128(7):
1175 - 1182.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Borges and R. Dingledine
Functional Organization of the GluR1 Glutamate Receptor Promoter
J. Biol. Chem.,
July 6, 2001;
276(28):
25929 - 25938.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|